Press Room MediaRoom New Survey Reveals the Widespread and Serious Impact of Moderate-to-Severe Atopic Dermatitis on People Living with the Disease - U.S. adults report issues with sleep, ability to work and feelings of depression and anxiety - Wed, 05 Oct 2016 08:30:00 -0400 Sanofi and Regeneron Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in The New England Journal of Medicine - Data to be presented today during a late breaking abstract session at the 25th Annual European Academy of Dermatology and Venereology (EADV) Congress - Sat, 01 Oct 2016 13:10:00 -0400 Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA Mon, 26 Sep 2016 06:48:00 -0400 Sanofi and Verily Life Sciences Announce Launch of Onduo, a Joint Venture to Develop Comprehensive Diabetes Management Platform - Joshua Riff, M.D., Named Chief Executive Officer - Mon, 12 Sep 2016 08:04:00 -0400 Sanofi Announces Q2 2016 Results Fri, 29 Jul 2016 08:00:00 -0400